PMC:7396557 / 60538-62698 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PMC-OGER-BB

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T337","span":{"begin":216,"end":221},"obj":"Body_part"},{"id":"T338","span":{"begin":482,"end":486},"obj":"Body_part"},{"id":"T339","span":{"begin":487,"end":491},"obj":"Body_part"},{"id":"T340","span":{"begin":496,"end":501},"obj":"Body_part"},{"id":"T341","span":{"begin":1339,"end":1344},"obj":"Body_part"},{"id":"T342","span":{"begin":1625,"end":1629},"obj":"Body_part"},{"id":"T343","span":{"begin":2024,"end":2028},"obj":"Body_part"}],"attributes":[{"id":"A337","pred":"fma_id","subj":"T337","obj":"http://purl.org/sig/ont/fma/fma9576"},{"id":"A338","pred":"fma_id","subj":"T338","obj":"http://purl.org/sig/ont/fma/fma9712"},{"id":"A339","pred":"fma_id","subj":"T339","obj":"http://purl.org/sig/ont/fma/fma9664"},{"id":"A340","pred":"fma_id","subj":"T340","obj":"http://purl.org/sig/ont/fma/fma49184"},{"id":"A341","pred":"fma_id","subj":"T341","obj":"http://purl.org/sig/ont/fma/fma9576"},{"id":"A342","pred":"fma_id","subj":"T342","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A343","pred":"fma_id","subj":"T343","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"A systematic evaluation of eight published randomized and controlled trials that included a total of 590 adult patients with viral pneumonia found that TRQI had advantages in terms of response rate, faster change of chest radiography, average length of stay, and other aspects (Pan, 2016). Research results from Jinzhi Liang et al. showed that there was no statistically significant difference in the clinical effect of combined TRQI and Ribavirin or TRQI alone in the treatment of hand-foot-and-mouth disease. Both treatments were superior to that of Ribavirin alone (Liang et al., 2013). Research by Wang Pei et al. showed that potential benefits of TRQI in the treatment of acute bronchitis included improved response rate, and reduced fever, cough, crackles, and X-ray shadow absorption (Wang et al., 2016). Research results of Lini Gao et al. showed that combined use of TRQI and Western medicines was more effective than Western medicines alone in the treatment of acute bronchitis and gave superior improvement of clinical symptoms (Gao et al., 2019). Hongli Jiang et al. showed by systematic evaluation that administration of TRQI to treat CAP on the basis of antibiotics and symptomatic treatment significantly improved clinical symptoms. Cough with expectoration was improved, the duration of fever was shortened and recovery of chest radiography and hemogram were promoted without significant adverse reactions (Jiang et al., 2009). Lian Xiong et al. showed by systematic evaluation that TRQI might have the same overall effect as some antibacterial drugs in treatment of patients with tuberculosis accompanied by lung infection, but improved efficacy was observed in combination with antibacterial drugs. This might be due to the bacteriostatic effects of TRQI and elimination of inflammatory mediators (Lian et al., 2018). A total of 14 trials and 954 patients were included in a study by Yunqing Zhong, and the results showed that combined use of TRQI and antibacterial drugs improved the clinical effects and lung function in AECOPD patients, reduced pCO2, and shortened the length of stay without serious adverse reactions (Zhong et al., 2010)."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T162","span":{"begin":216,"end":221},"obj":"Body_part"},{"id":"T163","span":{"begin":482,"end":486},"obj":"Body_part"},{"id":"T164","span":{"begin":487,"end":491},"obj":"Body_part"},{"id":"T165","span":{"begin":496,"end":501},"obj":"Body_part"},{"id":"T166","span":{"begin":1339,"end":1344},"obj":"Body_part"},{"id":"T167","span":{"begin":1625,"end":1629},"obj":"Body_part"},{"id":"T168","span":{"begin":2024,"end":2028},"obj":"Body_part"}],"attributes":[{"id":"A162","pred":"uberon_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"},{"id":"A163","pred":"uberon_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/UBERON_0002398"},{"id":"A164","pred":"uberon_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/UBERON_0002387"},{"id":"A165","pred":"uberon_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/UBERON_0000165"},{"id":"A166","pred":"uberon_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"},{"id":"A167","pred":"uberon_id","subj":"T167","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A168","pred":"uberon_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"A systematic evaluation of eight published randomized and controlled trials that included a total of 590 adult patients with viral pneumonia found that TRQI had advantages in terms of response rate, faster change of chest radiography, average length of stay, and other aspects (Pan, 2016). Research results from Jinzhi Liang et al. showed that there was no statistically significant difference in the clinical effect of combined TRQI and Ribavirin or TRQI alone in the treatment of hand-foot-and-mouth disease. Both treatments were superior to that of Ribavirin alone (Liang et al., 2013). Research by Wang Pei et al. showed that potential benefits of TRQI in the treatment of acute bronchitis included improved response rate, and reduced fever, cough, crackles, and X-ray shadow absorption (Wang et al., 2016). Research results of Lini Gao et al. showed that combined use of TRQI and Western medicines was more effective than Western medicines alone in the treatment of acute bronchitis and gave superior improvement of clinical symptoms (Gao et al., 2019). Hongli Jiang et al. showed by systematic evaluation that administration of TRQI to treat CAP on the basis of antibiotics and symptomatic treatment significantly improved clinical symptoms. Cough with expectoration was improved, the duration of fever was shortened and recovery of chest radiography and hemogram were promoted without significant adverse reactions (Jiang et al., 2009). Lian Xiong et al. showed by systematic evaluation that TRQI might have the same overall effect as some antibacterial drugs in treatment of patients with tuberculosis accompanied by lung infection, but improved efficacy was observed in combination with antibacterial drugs. This might be due to the bacteriostatic effects of TRQI and elimination of inflammatory mediators (Lian et al., 2018). A total of 14 trials and 954 patients were included in a study by Yunqing Zhong, and the results showed that combined use of TRQI and antibacterial drugs improved the clinical effects and lung function in AECOPD patients, reduced pCO2, and shortened the length of stay without serious adverse reactions (Zhong et al., 2010)."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T375","span":{"begin":125,"end":140},"obj":"Disease"},{"id":"T376","span":{"begin":131,"end":140},"obj":"Disease"},{"id":"T377","span":{"begin":482,"end":509},"obj":"Disease"},{"id":"T378","span":{"begin":487,"end":509},"obj":"Disease"},{"id":"T379","span":{"begin":496,"end":509},"obj":"Disease"},{"id":"T380","span":{"begin":683,"end":693},"obj":"Disease"},{"id":"T381","span":{"begin":977,"end":987},"obj":"Disease"},{"id":"T382","span":{"begin":1597,"end":1609},"obj":"Disease"},{"id":"T383","span":{"begin":1630,"end":1639},"obj":"Disease"}],"attributes":[{"id":"A375","pred":"mondo_id","subj":"T375","obj":"http://purl.obolibrary.org/obo/MONDO_0006012"},{"id":"A376","pred":"mondo_id","subj":"T376","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A377","pred":"mondo_id","subj":"T377","obj":"http://purl.obolibrary.org/obo/MONDO_0005779"},{"id":"A378","pred":"mondo_id","subj":"T378","obj":"http://purl.obolibrary.org/obo/MONDO_0005765"},{"id":"A379","pred":"mondo_id","subj":"T379","obj":"http://purl.obolibrary.org/obo/MONDO_0006858"},{"id":"A380","pred":"mondo_id","subj":"T380","obj":"http://purl.obolibrary.org/obo/MONDO_0003781"},{"id":"A381","pred":"mondo_id","subj":"T381","obj":"http://purl.obolibrary.org/obo/MONDO_0003781"},{"id":"A382","pred":"mondo_id","subj":"T382","obj":"http://purl.obolibrary.org/obo/MONDO_0018076"},{"id":"A383","pred":"mondo_id","subj":"T383","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"A systematic evaluation of eight published randomized and controlled trials that included a total of 590 adult patients with viral pneumonia found that TRQI had advantages in terms of response rate, faster change of chest radiography, average length of stay, and other aspects (Pan, 2016). Research results from Jinzhi Liang et al. showed that there was no statistically significant difference in the clinical effect of combined TRQI and Ribavirin or TRQI alone in the treatment of hand-foot-and-mouth disease. Both treatments were superior to that of Ribavirin alone (Liang et al., 2013). Research by Wang Pei et al. showed that potential benefits of TRQI in the treatment of acute bronchitis included improved response rate, and reduced fever, cough, crackles, and X-ray shadow absorption (Wang et al., 2016). Research results of Lini Gao et al. showed that combined use of TRQI and Western medicines was more effective than Western medicines alone in the treatment of acute bronchitis and gave superior improvement of clinical symptoms (Gao et al., 2019). Hongli Jiang et al. showed by systematic evaluation that administration of TRQI to treat CAP on the basis of antibiotics and symptomatic treatment significantly improved clinical symptoms. Cough with expectoration was improved, the duration of fever was shortened and recovery of chest radiography and hemogram were promoted without significant adverse reactions (Jiang et al., 2009). Lian Xiong et al. showed by systematic evaluation that TRQI might have the same overall effect as some antibacterial drugs in treatment of patients with tuberculosis accompanied by lung infection, but improved efficacy was observed in combination with antibacterial drugs. This might be due to the bacteriostatic effects of TRQI and elimination of inflammatory mediators (Lian et al., 2018). A total of 14 trials and 954 patients were included in a study by Yunqing Zhong, and the results showed that combined use of TRQI and antibacterial drugs improved the clinical effects and lung function in AECOPD patients, reduced pCO2, and shortened the length of stay without serious adverse reactions (Zhong et al., 2010)."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T567","span":{"begin":0,"end":1},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T568","span":{"begin":90,"end":91},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T569","span":{"begin":216,"end":221},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"},{"id":"T570","span":{"begin":278,"end":281},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9596"},{"id":"T571","span":{"begin":496,"end":501},"obj":"http://www.ebi.ac.uk/efo/EFO_0000825"},{"id":"T572","span":{"begin":1339,"end":1344},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"},{"id":"T573","span":{"begin":1625,"end":1629},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T574","span":{"begin":1625,"end":1629},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T575","span":{"begin":1829,"end":1833},"obj":"http://purl.obolibrary.org/obo/CLO_0001185"},{"id":"T576","span":{"begin":1836,"end":1837},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T577","span":{"begin":1891,"end":1892},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T578","span":{"begin":2024,"end":2028},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T579","span":{"begin":2024,"end":2028},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"A systematic evaluation of eight published randomized and controlled trials that included a total of 590 adult patients with viral pneumonia found that TRQI had advantages in terms of response rate, faster change of chest radiography, average length of stay, and other aspects (Pan, 2016). Research results from Jinzhi Liang et al. showed that there was no statistically significant difference in the clinical effect of combined TRQI and Ribavirin or TRQI alone in the treatment of hand-foot-and-mouth disease. Both treatments were superior to that of Ribavirin alone (Liang et al., 2013). Research by Wang Pei et al. showed that potential benefits of TRQI in the treatment of acute bronchitis included improved response rate, and reduced fever, cough, crackles, and X-ray shadow absorption (Wang et al., 2016). Research results of Lini Gao et al. showed that combined use of TRQI and Western medicines was more effective than Western medicines alone in the treatment of acute bronchitis and gave superior improvement of clinical symptoms (Gao et al., 2019). Hongli Jiang et al. showed by systematic evaluation that administration of TRQI to treat CAP on the basis of antibiotics and symptomatic treatment significantly improved clinical symptoms. Cough with expectoration was improved, the duration of fever was shortened and recovery of chest radiography and hemogram were promoted without significant adverse reactions (Jiang et al., 2009). Lian Xiong et al. showed by systematic evaluation that TRQI might have the same overall effect as some antibacterial drugs in treatment of patients with tuberculosis accompanied by lung infection, but improved efficacy was observed in combination with antibacterial drugs. This might be due to the bacteriostatic effects of TRQI and elimination of inflammatory mediators (Lian et al., 2018). A total of 14 trials and 954 patients were included in a study by Yunqing Zhong, and the results showed that combined use of TRQI and antibacterial drugs improved the clinical effects and lung function in AECOPD patients, reduced pCO2, and shortened the length of stay without serious adverse reactions (Zhong et al., 2010)."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T61015","span":{"begin":1168,"end":1179},"obj":"Chemical"},{"id":"T85357","span":{"begin":1547,"end":1566},"obj":"Chemical"},{"id":"T59965","span":{"begin":1561,"end":1566},"obj":"Chemical"},{"id":"T54909","span":{"begin":1696,"end":1715},"obj":"Chemical"},{"id":"T106","span":{"begin":1710,"end":1715},"obj":"Chemical"},{"id":"T64429","span":{"begin":1970,"end":1989},"obj":"Chemical"},{"id":"T20362","span":{"begin":1984,"end":1989},"obj":"Chemical"}],"attributes":[{"id":"A13341","pred":"chebi_id","subj":"T61015","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A19489","pred":"chebi_id","subj":"T85357","obj":"http://purl.obolibrary.org/obo/CHEBI_36047"},{"id":"A18175","pred":"chebi_id","subj":"T59965","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A59538","pred":"chebi_id","subj":"T54909","obj":"http://purl.obolibrary.org/obo/CHEBI_36047"},{"id":"A50837","pred":"chebi_id","subj":"T106","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A7390","pred":"chebi_id","subj":"T64429","obj":"http://purl.obolibrary.org/obo/CHEBI_36047"},{"id":"A35831","pred":"chebi_id","subj":"T20362","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"A systematic evaluation of eight published randomized and controlled trials that included a total of 590 adult patients with viral pneumonia found that TRQI had advantages in terms of response rate, faster change of chest radiography, average length of stay, and other aspects (Pan, 2016). Research results from Jinzhi Liang et al. showed that there was no statistically significant difference in the clinical effect of combined TRQI and Ribavirin or TRQI alone in the treatment of hand-foot-and-mouth disease. Both treatments were superior to that of Ribavirin alone (Liang et al., 2013). Research by Wang Pei et al. showed that potential benefits of TRQI in the treatment of acute bronchitis included improved response rate, and reduced fever, cough, crackles, and X-ray shadow absorption (Wang et al., 2016). Research results of Lini Gao et al. showed that combined use of TRQI and Western medicines was more effective than Western medicines alone in the treatment of acute bronchitis and gave superior improvement of clinical symptoms (Gao et al., 2019). Hongli Jiang et al. showed by systematic evaluation that administration of TRQI to treat CAP on the basis of antibiotics and symptomatic treatment significantly improved clinical symptoms. Cough with expectoration was improved, the duration of fever was shortened and recovery of chest radiography and hemogram were promoted without significant adverse reactions (Jiang et al., 2009). Lian Xiong et al. showed by systematic evaluation that TRQI might have the same overall effect as some antibacterial drugs in treatment of patients with tuberculosis accompanied by lung infection, but improved efficacy was observed in combination with antibacterial drugs. This might be due to the bacteriostatic effects of TRQI and elimination of inflammatory mediators (Lian et al., 2018). A total of 14 trials and 954 patients were included in a study by Yunqing Zhong, and the results showed that combined use of TRQI and antibacterial drugs improved the clinical effects and lung function in AECOPD patients, reduced pCO2, and shortened the length of stay without serious adverse reactions (Zhong et al., 2010)."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T448","span":{"begin":0,"end":289},"obj":"Sentence"},{"id":"T449","span":{"begin":290,"end":510},"obj":"Sentence"},{"id":"T450","span":{"begin":511,"end":589},"obj":"Sentence"},{"id":"T451","span":{"begin":590,"end":811},"obj":"Sentence"},{"id":"T452","span":{"begin":812,"end":1058},"obj":"Sentence"},{"id":"T453","span":{"begin":1059,"end":1247},"obj":"Sentence"},{"id":"T454","span":{"begin":1248,"end":1443},"obj":"Sentence"},{"id":"T455","span":{"begin":1444,"end":1716},"obj":"Sentence"},{"id":"T456","span":{"begin":1717,"end":1835},"obj":"Sentence"},{"id":"T457","span":{"begin":1836,"end":2160},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A systematic evaluation of eight published randomized and controlled trials that included a total of 590 adult patients with viral pneumonia found that TRQI had advantages in terms of response rate, faster change of chest radiography, average length of stay, and other aspects (Pan, 2016). Research results from Jinzhi Liang et al. showed that there was no statistically significant difference in the clinical effect of combined TRQI and Ribavirin or TRQI alone in the treatment of hand-foot-and-mouth disease. Both treatments were superior to that of Ribavirin alone (Liang et al., 2013). Research by Wang Pei et al. showed that potential benefits of TRQI in the treatment of acute bronchitis included improved response rate, and reduced fever, cough, crackles, and X-ray shadow absorption (Wang et al., 2016). Research results of Lini Gao et al. showed that combined use of TRQI and Western medicines was more effective than Western medicines alone in the treatment of acute bronchitis and gave superior improvement of clinical symptoms (Gao et al., 2019). Hongli Jiang et al. showed by systematic evaluation that administration of TRQI to treat CAP on the basis of antibiotics and symptomatic treatment significantly improved clinical symptoms. Cough with expectoration was improved, the duration of fever was shortened and recovery of chest radiography and hemogram were promoted without significant adverse reactions (Jiang et al., 2009). Lian Xiong et al. showed by systematic evaluation that TRQI might have the same overall effect as some antibacterial drugs in treatment of patients with tuberculosis accompanied by lung infection, but improved efficacy was observed in combination with antibacterial drugs. This might be due to the bacteriostatic effects of TRQI and elimination of inflammatory mediators (Lian et al., 2018). A total of 14 trials and 954 patients were included in a study by Yunqing Zhong, and the results showed that combined use of TRQI and antibacterial drugs improved the clinical effects and lung function in AECOPD patients, reduced pCO2, and shortened the length of stay without serious adverse reactions (Zhong et al., 2010)."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T231","span":{"begin":131,"end":140},"obj":"Phenotype"},{"id":"T232","span":{"begin":677,"end":693},"obj":"Phenotype"},{"id":"T233","span":{"begin":739,"end":744},"obj":"Phenotype"},{"id":"T234","span":{"begin":746,"end":751},"obj":"Phenotype"},{"id":"T235","span":{"begin":753,"end":761},"obj":"Phenotype"},{"id":"T236","span":{"begin":971,"end":987},"obj":"Phenotype"},{"id":"T237","span":{"begin":1248,"end":1253},"obj":"Phenotype"},{"id":"T238","span":{"begin":1303,"end":1308},"obj":"Phenotype"}],"attributes":[{"id":"A231","pred":"hp_id","subj":"T231","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A232","pred":"hp_id","subj":"T232","obj":"http://purl.obolibrary.org/obo/HP_0012388"},{"id":"A233","pred":"hp_id","subj":"T233","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A234","pred":"hp_id","subj":"T234","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A235","pred":"hp_id","subj":"T235","obj":"http://purl.obolibrary.org/obo/HP_0030830"},{"id":"A236","pred":"hp_id","subj":"T236","obj":"http://purl.obolibrary.org/obo/HP_0012388"},{"id":"A237","pred":"hp_id","subj":"T237","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A238","pred":"hp_id","subj":"T238","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"A systematic evaluation of eight published randomized and controlled trials that included a total of 590 adult patients with viral pneumonia found that TRQI had advantages in terms of response rate, faster change of chest radiography, average length of stay, and other aspects (Pan, 2016). Research results from Jinzhi Liang et al. showed that there was no statistically significant difference in the clinical effect of combined TRQI and Ribavirin or TRQI alone in the treatment of hand-foot-and-mouth disease. Both treatments were superior to that of Ribavirin alone (Liang et al., 2013). Research by Wang Pei et al. showed that potential benefits of TRQI in the treatment of acute bronchitis included improved response rate, and reduced fever, cough, crackles, and X-ray shadow absorption (Wang et al., 2016). Research results of Lini Gao et al. showed that combined use of TRQI and Western medicines was more effective than Western medicines alone in the treatment of acute bronchitis and gave superior improvement of clinical symptoms (Gao et al., 2019). Hongli Jiang et al. showed by systematic evaluation that administration of TRQI to treat CAP on the basis of antibiotics and symptomatic treatment significantly improved clinical symptoms. Cough with expectoration was improved, the duration of fever was shortened and recovery of chest radiography and hemogram were promoted without significant adverse reactions (Jiang et al., 2009). Lian Xiong et al. showed by systematic evaluation that TRQI might have the same overall effect as some antibacterial drugs in treatment of patients with tuberculosis accompanied by lung infection, but improved efficacy was observed in combination with antibacterial drugs. This might be due to the bacteriostatic effects of TRQI and elimination of inflammatory mediators (Lian et al., 2018). A total of 14 trials and 954 patients were included in a study by Yunqing Zhong, and the results showed that combined use of TRQI and antibacterial drugs improved the clinical effects and lung function in AECOPD patients, reduced pCO2, and shortened the length of stay without serious adverse reactions (Zhong et al., 2010)."}

LitCovid-PubTator

2_test

{"project":"2_test","denotations":[{"id":"32848729-27062962-39628386","span":{"begin":805,"end":809},"obj":"27062962"},{"id":"32848729-30124323-39628387","span":{"begin":1829,"end":1833},"obj":"30124323"},{"id":"32848729-21091297-39628388","span":{"begin":2154,"end":2158},"obj":"21091297"}],"text":"A systematic evaluation of eight published randomized and controlled trials that included a total of 590 adult patients with viral pneumonia found that TRQI had advantages in terms of response rate, faster change of chest radiography, average length of stay, and other aspects (Pan, 2016). Research results from Jinzhi Liang et al. showed that there was no statistically significant difference in the clinical effect of combined TRQI and Ribavirin or TRQI alone in the treatment of hand-foot-and-mouth disease. Both treatments were superior to that of Ribavirin alone (Liang et al., 2013). Research by Wang Pei et al. showed that potential benefits of TRQI in the treatment of acute bronchitis included improved response rate, and reduced fever, cough, crackles, and X-ray shadow absorption (Wang et al., 2016). Research results of Lini Gao et al. showed that combined use of TRQI and Western medicines was more effective than Western medicines alone in the treatment of acute bronchitis and gave superior improvement of clinical symptoms (Gao et al., 2019). Hongli Jiang et al. showed by systematic evaluation that administration of TRQI to treat CAP on the basis of antibiotics and symptomatic treatment significantly improved clinical symptoms. Cough with expectoration was improved, the duration of fever was shortened and recovery of chest radiography and hemogram were promoted without significant adverse reactions (Jiang et al., 2009). Lian Xiong et al. showed by systematic evaluation that TRQI might have the same overall effect as some antibacterial drugs in treatment of patients with tuberculosis accompanied by lung infection, but improved efficacy was observed in combination with antibacterial drugs. This might be due to the bacteriostatic effects of TRQI and elimination of inflammatory mediators (Lian et al., 2018). A total of 14 trials and 954 patients were included in a study by Yunqing Zhong, and the results showed that combined use of TRQI and antibacterial drugs improved the clinical effects and lung function in AECOPD patients, reduced pCO2, and shortened the length of stay without serious adverse reactions (Zhong et al., 2010)."}

PMC:7396557 / 60538-62698 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7396557 / 60538-62698 JSON TXT